Ras

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

(-)-Rasfonin

Cat. No.: HY-121532

(-)-Rasfonin is a fungal secondary metabolite and inhibits small G proteins Ras. (-)-Rasfonin induces **apoptosis**, **necrosis** and **autophagy** in ACHN cells (a renal carcinoma cell line).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-CE3F4

Cat. No.: HY-108539A

(R)-CE3F4 is a potent and selective inhibitor of exchange protein directly activated by cAMP isoform 1 (**Epac1**), with an IC_{50} of 4.2 μM, with 10-fold selectivity for Epac1 over Epac2 (IC_{50}, 44 μM). (R)-CE3F4 is more potent than racemic CE3F4 and (S)-CE3F4.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Rac)-Antineoplaston A10

Cat. No.: HY-128553A

(rac)-Antineoplaston A10 is the racemate of Antineoplaston A10. Antineoplaston A10 is a **Ras** inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

1A-116

Cat. No.: HY-104064

1A-116 is a **Rac1** inhibitor, with antitumoral and antimetastatic effects in several types of cancer, such as breast cancer. 1A-116 prevents Rac1-regulated processes involved in the primary tumorigenesis and metastatic processes .



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

6H05

Cat. No.: HY-12408

6H05 is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C). IC50 value: Target: K-Ras G12C 6H05 gives the greatest degree of modification, which allosterically modifies the oncogenic G12C mutant of highly homologous protein H-Ras without affecting wild-type K-Ras .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

6H05 (TFA)

Cat. No.: HY-12408A

6H05 TFA is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C). IC50 value: Target: K-Ras G12C 6H05 gives the greatest degree of modification, which allosterically modifies the oncogenic G12C mutant of highly homologous protein H-Ras without affecting wild-type K-Ras .



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

8-CPT-2Me-cAMP sodium

Cat. No.: HY-107543

8-CPT-2Me-cAMP sodium is a selective activator of **exchange proteins activated by cAMP (Epac)**, the cAMP sensitive guanine nucleotide exchange factors (GEFs) for the small GTPases Rap1 and Rap2.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Adagrasib

(MRTX849)

Cat. No.: HY-130149

Adagrasib (MRTX849) is a potent, orally-available, and mutation-selective covalent inhibitor of **KRAS G12C** with potential antineoplastic activity.



Purity: 99.85%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 500 mg

Alkannin

Cat. No.: HY-119874

Alkannin is a potent and specific inhibitor of tumor-specific pyruvate kinase-M2 (PKM2). Alkannin does not inhibit PKM1 and pyruvate kinase-L (PKL). Alkannin acts as a potential anticancer agent.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Antineoplaston A10

Cat. No.: HY-128553

Antineoplaston A10, a naturally occurring substance in human body, is a **Ras** inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.



Purity: 98.58%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

APS6-45

Cat. No.: HY-124944

APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ARS-1323

Cat. No.: HY-U00416

ARS-1323, the racemate of ARS-1620, is a novel inhibitor of **mutant K-ras G12C** extracted from patent WO 2015054572 A1.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

ARS-1323-alkyne

Cat. No.: HY-128522

ARS-1323-alkyne, a **switch-II pocket (S-IIP)** inhibitor, is a conformational specific chemical reporter of $KRAS^{G12C}$ nucleotide state in living cells.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ARS-1620

Cat. No.: HY-U00418

ARS-1620 is an atropisomeric selective $KRAS^{G12C}$ inhibitor with desirable pharmacokinetics.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

ARS-1630

Cat. No.: HY-U00417

ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of **mutant K-ras G12C** extracted from patent WO 2015054572 A1.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ARS-853

Cat. No.: HY-19706

ARS-853 is a cell-active, selective, covalent **KRAS G12C** inhibitor with an IC_{50} of 2.5 μM. ARS-853 inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

ASP2453

Cat. No.: HY-132966

ASP2453 is a potent, selective and covalent **KRAS G12C** inhibitor. ASP2453 inhibits the Son of Sevenless (SOS)-mediated interaction between **KRAS G12C and Raf** with an IC_{50} value of 40 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Atranorin

Cat. No.: HY-N2907

Atranorin is a lichen secondary metabolite. Atranorin inhibits lung cancer cell motility and tumorigenesis by affecting AP-1, Wnt, and STAT signaling and suppressing **RhoGTPase** activity.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Atrovastatin-PEG3-FITC

Cat. No.: HY-134977

Atrovastatin-PEG3-FITC (compound S31) is a **KRAS-PDEδ** interaction inhibitor. Atrovastatin-PEG3-FITC acts as a ligand in fluorescence anisotropy assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZA1

(Rac1/Cdc42-IN-1)

Cat. No.: HY-136383

AZA1 is a potent dual inhibitor of **Rac1** and **Cdc42**. AZA1 induces prostate cancer cells apoptosis and inhibits prostate cancer cells proliferation, migration and invasion.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BAY-293

Cat. No.: HY-114398

BAY-293, a valuable chemical probe, blocks **RAS** activation via disruption of the **KRAS-SOS1** interaction with an **IC_{50}** of 21 nM. BAY-293 is a potent inhibitor of Son of Sevenless 1 (**SOS1**). SOS1 is the guanine nucleotide exchange factor (GEF) and activator of RAS.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BDP9066

Cat. No.: HY-111424

BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase **MRCK** inhibitor with an **IC_{50}** of 64 nM for MRCKβ in SCC12 cells, **K_i** values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BI-2852

Cat. No.: HY-126247

BI-2852 is a **KRAS** inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based drug design with nanomolar affinity.



Purity: 98.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BI-3406

Cat. No.: HY-125817

BI-3406 (compound I-6) is an orally active, highly potent and selective inhibitor of the interaction between **KRAS** and **Son of Sevenless 1 (SOS1)** with an **IC_{50}** of 6 nM. BI-3406 potently reduces the formation of GTP-loaded KRAS, and inhibits **MAPK** pathway signaling.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BQU57

Cat. No.: HY-12875

BQU57 shows selective inhibition for Ral relative to Ras or Rho and inhibit xenograft tumor growth similar to depletion of Ral by siRNA. The IC50 for BQU57 of 2.0 μM in H2122 and 1.3 μM in H358.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CASIN

Cat. No.: HY-12874

CASIN is a selective GTPase Cdc42 inhibitor with IC50 of 2 uM.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CCG-100602

Cat. No.: HY-120855

CCG-100602 is a specific inhibitor of myocardin-related transcription factor A/serum response factor (**MRTF-A/SRF**) signaling. CCG-100602 specifically block MRTF-A nuclear localization and thus inhibit the fibrogenic transcription factor SRF.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg, 50 mg, 100 mg

CCG-1423

Cat. No.: HY-13991

CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

CCG-203971

Cat. No.: HY-108361

CCG-203971 is a second-generation **Rho/MRTF/SRF** pathway inhibitor. CCG-203971 potently targets RhoA/C-activated SRE-luciferase (IC_{50} =6.4 μM). CCG-203971 inhibits PC-3 cell migration with an IC_{50} of 4.2 μM. Potential anti-metastasis Agent.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

CCG-222740

Cat. No.: HY-121750

CCG-222740 is an orally active and selective **Rho/myocardin-related transcription factor (MRTF)** pathway inhibitor. CCG-222740 is also a potent inhibitor of alpha-smooth muscle actin protein expression. CCG-222740 effectively reduces fibrosis in skin and blocks melanoma metastasis.



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CID-1067700

(ML282) Cat. No.: HY-13452

CID-1067700 (ML282) is a pan **GTPase** inhibitor, and competitively inhibits Ras-related in brain 7 (**Rab7**) with a K_i of 13 nM.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

CID44216842

(Cdc42-IN-1) Cat. No.: HY-136379

CID44216842 (Cdc42-IN-1) is a potent **Cdc42**-selective guanine nucleotide binding lead inhibitor. The EC_{50}s for Cdc42 WT and Cdc42Q61L mutant are 1.0 and 1.2 μM in GTP binding assay, respectively.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CMC2.24

(TRB-N0224) Cat. No.: HY-120793

CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting **Ras** activation and its downstream effector ERK1/2 pathway.



Purity: 96.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Deltarasin

Cat. No.: HY-15747

Deltarasin is an inhibitor of **KRAS-PDEδ** interaction with K_d of 38 nM for binding to purified PDEδ.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Deltarasin hydrochloride

Cat. No.: HY-15747A

Deltarasin hydrochloride is an inhibitor of **KRAS-PDEδ**interaction with K_d of 38 nM for binding to purified PDEδ.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Diazepinomicin

(ECO-4601; TLN-4601; BU 4664L) Cat. No.: HY-N6674

Diazepinomicin (TLN-4601) is a secondary metabolite produced by Micromonospora sp. Diazepinomicin (TLN-4601) inhibits the EGF-induced Ras-ERK MAPK signaling pathway and induces apoptosis. An anti-tumor agent for K-Ras mutant models.



Purity: 98.04%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Digeranyl bisphosphonate

(DGBP) Cat. No.: HY-U00145

Digeranyl bisphosphonate (DGBP) is a potent geranylgeranylpyrophosphate (GGPP) synthase inhibitor, which inhibits geranylgeranylation of Rac1.



Purity: 81.48%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

EHop-016

Cat. No.: HY-12810

EHop-016 is a potent and selective **Rac GTPase Rac1** and **Rac3** inhibitor. EHop-016 inhibits **Rac1** activity with an IC_{50} of 1.1 μM in MDA-MB-435 cells. EHop-016 inhibits Vav2 interaction with Rac, Rac-activated PAK1, lamellipodia formation, and cell migration.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

EHT 1864

Cat. No.: HY-16659

EHT 1864 is an inhibitor of **Rac family small GTPases**. EHT 1864 directly binds and impairs the ability of this small GTPase to engage critical downstream effectors required for growth transformation.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

EPAC 5376753

Cat. No.: HY-111446

EPAC 5376753 is an allosterically inhibitor of **Epac** which inhibits Epac1 with an IC_{50} of 4 μM in Swiss 3T3 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

ESI-08

Cat. No.: HY-136172

ESI-08 is a potent and selective **EPAC** antagonist, which can completely inhibit both **EPAC1** and **EPAC2** (IC_{50} of 8.4 μM) activity. ESI-08 selectively blocks cAMP-induced **EPAC** activation, but does not inhibit cAMP-mediated PKA activation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FTI-277

Cat. No.: HY-15872

FTI-277 is an inhibitor of **farnesyl transferase (FTase)**; a highly potent Ras CAAX peptidomimetic which antagonizes both **H-** and **K-Ras oncogenic signaling**. FTI-277 can inhibit **hepatitis delta virus (HDV)** infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FTI-277 hydrochloride

Cat. No.: HY-15872A

FTI-277 hydrochloride is an inhibitor of **farnesyl transferase (FTase)**; a highly potent Ras CAAX peptidomimetic which antagonizes both **H-** and **K-Ras oncogenic signaling**. FTI-277 hydrochloride can inhibit **hepatitis delta virus (HDV)** infection.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Garsorasib

Cat. No.: HY-145571

Garsorasib is a potent inhibitor of **KRAS G12C** with an IC_{50} of 10 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GDC-6036

Cat. No.: HY-145928

GDC-6036 (compound 17a) is a potent **K-Ras G12C** inhibitor with an IC_{50} of <0.01 μM. GDC-6036 has an EC_{50} of 2 nM in K-Ras G12C-alkylation HCC1171 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

GGTI-286

Cat. No.: HY-115489

GGTI-286, a potent and cell-permeable **GGTase I** inhibitor, is 25-fold more potent (IC_{50}=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GGTI298

Cat. No.: HY-100876

GGTI298 is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, strongly inhibiting the processing of geranylgeranylated Rap1A with little effect on processing of farnesylated Ha-Ras, with IC_{50} values of 3 and > 20 μM in vivo, respectively.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

GGTI298 Trifluoroacetate

Cat. No.: HY-15871

GGTI298 Trifluoroacetate is a CAAZ peptidomimetic geranylgeranyltransferase I (**GGTase I**) inhibitor, which can inhibit **Rap1A** with IC_{50} of 3 μM; little effect on **Ha-Ras** with IC_{50} of >20 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

HJC0197

Cat. No.: HY-117958

HJC0197 is a potent **Epac1** (exchange protein directly activated by cAMP 1) and **Epac2** (IC_{50}=5.9 μM for Epac2) antagonist. HJC0197 selectively blocks cAMP-induced Epac activation.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JDQ-443

(NVP-JDQ443)

Cat. No.: HY-139612

JDQ-443 is an orally active, potent, selective, and covalent **KRAS G12C** inhibitor (extracted from patent WO2021120890A1). JDQ-443 shows antitumor activity.



Purity: 98.94%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

K-Ras G12C-IN-1

Cat. No.: HY-18604

K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1. IC50 value: Target: K-ras G12C inhibitor.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

K-Ras G12C-IN-2

Cat. No.: HY-18605

K-Ras G12C-IN-2 is an irreversible covalent **K-Ras G12C** inhibitor.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

K-Ras G12C-IN-3

Cat. No.: HY-18606

K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

K-Ras G12C-IN-4

Cat. No.: HY-128771

K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of **KRAS^{G12C}**.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

K-Ras(G12C) inhibitor 12

Cat. No.: HY-18707

K-Ras(G12C) inhibitor 12 is a K-Ras(G12C) inhibitor, the half-maximum effective concentration (EC50) for K-Ras(G12C) inhibitor 12 in H1792 cells is 0.32 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

K-Ras(G12C) inhibitor 6

Cat. No.: HY-107841

K-Ras(G12C) inhibitor 6 is an irreversible, allosteric inhibitor of the **K-Ras(G12C)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

K-Ras(G12C) inhibitor 9

Cat. No.: HY-12446

K-Ras (G12C) inhibitor 9 is an allosteric inhibitor of the K-Ras (G12C).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

K-Ras-IN-1

Cat. No.: HY-18674

K-Ras-IN-1 is a **K-Ras** inhibitor. K-Ras-IN-1 binds to K-Ras (WT), K-Ras (G12D), K-Ras (G12V), and H-Ras. K-Ras-IN-1 has potential for the research of pancreatic, colon and lung carcinomas.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

K20

Cat. No.: HY-115907

K20 is a potent and selective **KRas G12C** inhibitor with an **IC_{50}** of 1.16 μM. K20 shows anticancer activity in H358 cells (IC_{50}= 0.78 μM). K20 decreases the levels of phosphorylated Erk and leads to cancer cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ketoconazole

(Ketoconazol; R 41400)

Cat. No.: HY-B0105

Ketoconazole (R-41400) is an imidazole anti-fungal agent, a CYP3A4 and CYP24A1 inhibitor.



Purity: 99.47%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g, 5 g

Ketoconazole-d4

(Ketoconazol-d4; R 41400-d4) Cat. No.: HY-B0105S1

Ketoconazole-d4 (Ketoconazol-d4) is the deuterium labeled Ketoconazole. Ketoconazole (R-41400) is an imidazole anti-fungal agent, a CYP3A4 and CYP24A1 inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ketoconazole-d8

Cat. No.: HY-B0105S

Ketoconazole-d8 is the deuterium labeled Ketoconazole. Ketoconazole (R-41400) is an imidazole anti-fungal agent, a CYP3A4 and CYP24A1 inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

Kobe0065

Cat. No.: HY-15716

Kobe0065 is a novel and effective inhibitor of **Ras-Raf interaction**, competitively inhibiting the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i value of 46±13 μM.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Kobe2602

Cat. No.: HY-15717

Kobe2602 is a **Ras-Raf interaction** inhibitor. Kobe2602 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i of 149 μM. Kobe2602 has antitumor activity.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 250 mg

KRA-533

Cat. No.: HY-138188

KRA-533 is a potent **KRAS** agonist. KRA-533 binds to the GTP/GDP binding pocket in the KRAS protein to prevent GTP cleavage, resulting in the accumulation of constitutively active GTP-bound KRAS that triggers both **apoptotic** and **autophagic** cell death pathways in cancer cells.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KRas G12C inhibitor 1

Cat. No.: HY-112491

KRas G12C inhibitor 1 is a compound that inhibits **KRas G12C**, extracted from patent US 20180072723 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 13

Cat. No.: HY-126292

KRAS G12C inhibitor 13 is a **KRAS G12C** inhibitor extracted from patent WO2018143315A1, compound 30.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 14

Cat. No.: HY-125872

KRAS G12C inhibitor 14 is a potent **KRAS G12C** inhibitor extracted from patent WO2019110751A1, compound 17, has an IC_{50} of 18 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 15

Cat. No.: HY-125873

KRAS G12C inhibitor 15 is a potent **KRAS G12C** inhibitor extracted from patent WO2019110751A1, compound 22, has an IC_{50} of 5 nM.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KRAS G12C inhibitor 16

Cat. No.: HY-125874

KRAS G12C inhibitor 16 is a potent **KRAS G12C** inhibitor extracted from patent WO2019110751A1, compound 39, has an IC_{50} of 97 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 17

Cat. No.: HY-125875

KRAS G12C inhibitor 17 is a potent **KRAS G12C** inhibitor extracted from patent WO2019110751A1, compound 82, has an IC_{50} of 5 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 18

Cat. No.: HY-132979

KRAS G12C inhibitor 18 is a potent and orally active **KRAS G12C** inhibitor. Anti-tumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 19

Cat. No.: HY-132980

KRAS G12C inhibitor 19 is a potent inhibitor of **KRAS G12C**. KRAS G12C inhibitor 19 significantly inhibits tumor growth (extracted from patent WO2021118877A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRas G12C inhibitor 2

Cat. No.: HY-112492

KRas G12C inhibitor 2 is a compound that inhibits **KRas G12C**, extracted from patent US 20180072723 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 20

Cat. No.: HY-145017

KRAS G12C inhibitor 20 is a **KRAS G12C** inhibitor extracted from patent CN112694475A, example 1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 21

Cat. No.: HY-145018

KRAS G12C inhibitor 21 is a **KRAS G12C** inhibitor extracted from patent WO2021219090A1, example 7.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 22

Cat. No.: HY-145019

KRAS G12C inhibitor 22 is a **KRAS G12C** inhibitor extracted from patent WO2021219072A1, example 120.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 23

Cat. No.: HY-145020

KRAS G12C inhibitor 23 is a **KRAS G12C** inhibitor. KRAS G12C inhibitor 23 inhibits H358 cells with an IC_{50} of 491 nM (WO2021218939A1, compound 1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 24

Cat. No.: HY-145021

KRAS G12C inhibitor 24 is a potent **KRAS G12C** inhibitor. KRAS G12C inhibitor 24 inhibits KRAS G12C/SOS1 interaction with an IC_{50} of50 nM (CN113563323A, compound 1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 25

Cat. No.: HY-145022

KRAS G12C inhibitor 25 is a **KRAS G12C** inhibitor. KRAS G12C inhibitor 25 inhibits SOSl-assisted GDP/GTP exchanging activity of KRAS-G12C mutant (IC_{50}=0.48 nM). From WO2021216770A1 compound 3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 26

Cat. No.: HY-142457

KRAS G12C inhibitor 26 is a **KRAS G12C** inhibitor with antitumor effects (WO2021109737).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 27

Cat. No.: HY-142458

KRAS G12C inhibitor 27 is a **KRAS G12C** inhibitor with antitumor effects (WO2021109737).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 28

Cat. No.: HY-142460

KRAS G12C inhibitor 28 is a **KRAS G12C** inhibitor with an IC_{50} of 57 nM. KRAS G12C inhibitor 28 has antitumor effects (WO2021113595A1; Example 1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 29

Cat. No.: HY-142478

KRAS G12C inhibitor 29 is a **KRAS G12C** inhibitor extracted from patent WO2021252339A1, compound 3. KRAS G12C inhibitor 29 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRas G12C inhibitor 3

Cat. No.: HY-112493

KRas G12C inhibitor 3 is a compound that inhibits **KRas G12C**, extracted from patent US 20180072723 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 30

Cat. No.: HY-142481

KRAS G12C inhibitor 30 is a **KRAS G12C** inhibitor extracted from patent WO2021252339A1, compound 2. KRAS G12C inhibitor 30 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 31

Cat. No.: HY-142485

KRAS G12C inhibitor 31 is a **KRAS G12C** inhibitor extracted from patent WO2021252339A1, compound 1. KRAS G12C inhibitor 31 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 32

Cat. No.: HY-142487

KRAS G12C inhibitor 32, an eight membered heterocyclic compound containing N, is a potent **KRAS G12C** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 33

Cat. No.: HY-142490

KRAS G12C inhibitor 33 is a **KRAS G12C** inhibitor extracted from patent WO2021244603A1, compound 1. KRAS G12C inhibitor 33 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 34

Cat. No.: HY-142511

KRAS G12C inhibitor 34 is a **KRAS G12C** inhibitor extracted from patent WO2021239058A1, compound Z1. KRAS G12C inhibitor 34 can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 35

Cat. No.: HY-143588

KRAS G12C inhibitor 35 is a potent inhibitor of **KRAS G12C**. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 36

Cat. No.: HY-143589

KRAS G12C inhibitor 36 is a potent inhibitor of **KRAS G12C**. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 37

Cat. No.: HY-143590

KRAS G12C inhibitor 37 is a potent inhibitor of **KRAS G12C**. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 38

Cat. No.: HY-143591

KRAS G12C inhibitor 38 is a potent inhibitor of **KRAS G12C**. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 39

Cat. No.: HY-143592

KRAS G12C inhibitor 39 is a potent inhibitor of **KRAS G12C**. KRas is a highly attractable target of the pharmaceutical industry for cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRas G12C inhibitor 4

Cat. No.: HY-112494

KRas G12C inhibitor 1 is a compound that inhibits **KRas G12C**, extracted from patent US 20180072723 A1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 40

Cat. No.: HY-143594

KRAS G12C inhibitor 40 is a potent inhibitor of **KRAS G12C**. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 41

Cat. No.: HY-143596

KRAS G12C inhibitor 41 is a potent inhibitor of **KRAS G12C**. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 42

Cat. No.: HY-143598

KRAS G12C inhibitor 42 is a potent inhibitor of **KRAS G12C**. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12C inhibitor 5

Cat. No.: HY-114168

KRAS G12C inhibitor 5 is a **KRas G12C** inhibitor extracted from patent WO2017201161A1, Compound example 147.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12D inhibitor 1

Cat. No.: HY-134811

KRAS G12D inhibitor 1 (example 243) is a **KRAS G12D** inhibitor, with an IC_{50} of 0.8 nM for KRAS G12D-mediated ERK phosphorylation.



Purity: 98.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

KRAS G12D inhibitor 10

Cat. No.: HY-143603

KRAS G12D inhibitor 10 is a potent inhibitor of **KRAS G12D**. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12D inhibitor 11

Cat. No.: HY-143604

KRAS G12D inhibitor 11 is a potent inhibitor of **KRAS G12D**. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12D inhibitor 12

Cat. No.: HY-143606

KRAS G12D inhibitor 12 is a potent inhibitor of **KRAS G12D**. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12D inhibitor 13

Cat. No.: HY-143607

KRAS G12D inhibitor 13 is a potent inhibitor of **KRAS G12D**. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12D inhibitor 14

Cat. No.: HY-144661

KRAS G12D inhibitor 14 is a potent **KRAS G12D** inhibitor with a K_D of 33 nM for binding to KRAS G12D protein. KRAS G12D inhibitor 14 decreases the active form of KRAS G12D (KRAS G12D-GTP) but not KRAS G13D.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12D inhibitor 3

Cat. No.: HY-115880

KRAS G12D inhibitor 3 is a **KRAS G12D** inhibitor with an IC_{50} of <500 nM. KRAS G12D inhibitor 3 has antitumor effects (WO2022002102A1; compound 146).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12D inhibitor 3 TFA

Cat. No.: HY-115880A

KRAS G12D inhibitor 3 TFA is a **KRAS G12D** inhibitor with an IC_{50} of <500 nM. KRAS G12D inhibitor 3 TFA has antitumor effects (WO2022002102A1; compound 146).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12D inhibitor 5

Cat. No.: HY-139894

KRAS G12D inhibitor 5 is a **KRAS G12D** inhibitor for the potential treatment of pancreatic cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12D inhibitor 6

Cat. No.: HY-139910

KRAS G12D inhibitor 6 is a potent inhibitor of **KRAS G12D** (extracted from patent WO2021108683A1, compound 112) .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12D inhibitor 7

Cat. No.: HY-139911

KRAS G12D inhibitor 7 is a potent inhibitor of **KRAS G12D** (extracted from patent WO2021108683, compound 114) .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12D inhibitor 8

Cat. No.: HY-143599

KRAS G12D inhibitor 8 is a potent inhibitor of **KRAS G12D**. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS G12D inhibitor 9

Cat. No.: HY-143602

KRAS G12D inhibitor 9 is a potent inhibitor of **KRAS G12D**. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS inhibitor-10

Cat. No.: HY-138295

KRAS inhibitor-10 selectively and effectively inhibit **RAS** proteins, and particularly KRAS proteins.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KRAS inhibitor-11

Cat. No.: HY-145436

KRAS inhibitor-11 (compound 12) is a **KRAS** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS inhibitor-4

Cat. No.: HY-130260

KRAS inhibitor-4 (compound F12) is a potent **KRAS** inhibitor and developed as anticancer agents.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS inhibitor-6

Cat. No.: HY-135864

KRAS inhibitor-6 is a potent **KRAS G12C** inhibitor, extracted from patent WO2017087528A1, compound A.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS inhibitor-7

Cat. No.: HY-135865

KRAS inhibitor-7 is a potent **KRAS G12C** inhibitor, extracted from patent WO2017087528A1, compound B.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS inhibitor-8

Cat. No.: HY-135866

KRAS inhibitor-8 is a potent **KRAS G12C** inhibitor, extracted from patent WO2017087528A1, compound C.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KRAS inhibitor-9

Cat. No.: HY-137497

KRAS inhibitor-9, a potent **KRAS** inhibitor (K_d=92 μM), blocks the formation of GTP-KRAS and downstream activation of KRAS. KRAS inhibitor-9 binds to KRAS G12D, KRAS G12C and KRAS Q61H protein with a moderate binding affinity.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KRAS mutant protein inhibitor 1

Cat. No.: HY-132920

KRAS mutant protein inhibitor 1 is a **KRAS** mutant protein inhibitor for potential treatment in cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LC-2

Cat. No.: HY-137516

LC-2 is a potent and first-in-class **von Hippel-Lindau**-based PROTAC capable of degrading endogenous **KRAS G12C**, with DC_{50}s between 0.25 and 0.76 μM.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Lonafarnib

(Sch66336)

Cat. No.: HY-15136

Lonafarnib (Sch66336) is a potent and orally active **farnesyl transferase (FTase)** inhibitor. Lonafarnib inhibits the activities of **H-ras**, **K-ras** and **N-ras** with IC_{50} values of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib also has anti-hepatitis delta virus (HDV) activities.



Purity: 98.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg

Manumycin A

Cat. No.: HY-N6796

Manumycin A is an antibiotic. Manumycin A acts as a selective, competitive inhibitor of protein **farnesyltransferase (FTase)** with respect to farnesylpyrophosphate (K_i =1.2 μM), and as a noncompetitive inhibitor with respect to the **Ras** protein.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MBQ-167

Cat. No.: HY-112842

MBQ-167 is a dual **Rac/Cdc42** inhibitor, with IC_{50}s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MCP110

Cat. No.: HY-123673

MCP110 is an inhibitor of **Ras/Raf-1** interaction. MCP110 blocks the interaction of Ras with Raf. MCP110 disrupts this interaction might can be used for the research of human tumors.



Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Methylophiopogonanone B

Cat. No.: HY-N2438

Methylophiopogonanone B, homoisoflavonoid, is extracted from the root of Ophiopogon japonicas, shows high antioxidant ability.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

ML-098

(CID-7345532)

Cat. No.: HY-19800

ML-098 (CID-7345532) is an activator of the GTP-binding protein **Rab7** with an EC_{50} of 77.6 nM.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

ML-099

(CID-888706)

Cat. No.: HY-124306

ML-099 (CID-888706) is a pan **Ras-related GTPases** activator that can activate **Rac1**, **cell division cycle 42**, **Ras**, **Rab7**, and **Rab-2A**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ML141

(CID-2950007)

Cat. No.: HY-12755

ML141 (CID-2950007) is a potent, allosteric, selective and reversible non-competitive inhibitor of **Cdc42 GTPase**. ML141 inhibits Cdc42 wild type and Cdc42 Q61L mutant with EC_{50}s of 2.1 and 2.6 μM, respectively.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MLS-573151

(MLS000573151)

Cat. No.: HY-113849

MLS-573151 (MLS000573151) is a selective GTPase **Cdc42** inhibitor with an EC_{50} of 2 μM. MLS-573151 is inactive against other GTPases family members, such as Rab2, Rab7, H-Ras, Rac1, Rac 2 and RhoA wild-type. MLS-573151 acts by blocking the binding of GTP to Cdc42.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MLS000532223

Cat. No.: HY-117149

MLS000532223 is a high affinity, selective inhibitor of **Rho family GTPases**, with EC_{50} values ranging from 16 μM to 120 μM. MLS000532223 prevents GTP binding to several GTPases.



Purity: 99.47%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MRTX-1257

Cat. No.: HY-114436

MRTX-1257 is a selective, irreversible, covalent and orally active **KRAS G12C** inhibitor, with an IC_{50} of 900 pM for KRAS dependent ERK phosphorylation in H358 cells.



Purity: 99.14%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

MRTX-EX185

Cat. No.: HY-145962

MRTX-EX185 is a potent inhibitor of **GDP-loaded KRAS** and **KRAS(G12D)**, with an IC_{50} of 90 nM for KRAS(G12D). MRTX-EX185 also binds **GDP-loaded HRAS**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

MRTX0902

Cat. No.: HY-145926

MRTX0902 is a potent **SOS1** inhibitor with an IC_{50} of 46 nM (WO2021127429A1; Example 12-10).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

MRTX1133

Cat. No.: HY-134813

MRTX1133 is a noncovalent, potent, and selective **KRAS G12D** inhibitor. MRTX1133 optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated K_D against KRAS G12D of 0.2 pM.



Purity: 99.29%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

MRTX1133 formic

Cat. No.: HY-134813A

MRTX1133 formic is a noncovalent, potent, and selective **KRAS G12D** inhibitor. MRTX1133 formic optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated K_D against KRAS G12D of 0.2 pM.



Purity: 98.23%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

MRTX849 acid

Cat. No.: HY-139402

MRTX849 acid, a derivative of MRTX849, can be used in the synthesis of PROTAC LC-2 (HY-137516). LC-2 is a potent and first-in-class PROTAC capable of degrading endogenous KRAS G12C (DC^{50}s between 0.25 and 0.76 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MRTX849 ethoxypropanoic acid

Cat. No.: HY-139403

MRTX849 ethoxypropanoic acid incorporates a ligand for KRAS G12C, and a PROTAC linker. MRTX849 ethoxypropanoic acid can be used in the synthesis of PROTAC LC-2 (HY-137516).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC 23766

Cat. No.: HY-15723

NSC 23766 is a cell-permeable, reversible and specific inhibitor of **Rac GTPase**, used for cancer treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC 23766 trihydrochloride

Cat. No.: HY-15723A

NSC 23766 trihydrochloride is an inhibitor of **Rac1** activation.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

NSC-658497

Cat. No.: HY-19539

NSC-658497 is an effective inhibitor of Ras-GEF, **SOS1**. NSC-658497 binds to SOS1, competitively suppresses SOS1-Ras interaction, and dose-dependently inhibits SOS1 GEF activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Oncrasin-1

Cat. No.: HY-16662

Oncrasin-1 is a potent and effective anticancer inhibitor that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations; also led to abnormal aggregation of PKCι in nucleus of sensitive cells but not in resistant cells.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Pan-RAS-IN-1

Cat. No.: HY-101295

Pan-RAS-IN-1 is a **pan-Ras** inhibitor that disrupts the interaction of Ras proteins and their effectors.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PHT-7.3

Cat. No.: HY-128590

PHT-7.3 is a selective inhibitor of **connector enhancer of kinase suppressor of Ras 1 (Cnk1)** pleckstrin homology (PH) domain (K_d=4.7 μM). PHT-7.3 inhibits mut-KRas, but not wild-type KRas cancer cell and tumor growth and signaling. PHT-7.3 has antitumor activity.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PROTAC K-Ras Degrader-1

Cat. No.: HY-129523

PROTAC K-Ras Degrader-1 (Compound 518) is potent **K-Ras** degrader based on **Cereblon** E3 ligand, exhibits ≥70% degradation efficacy in SW1573 cells.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PROTAC SOS1 degrader-1

Cat. No.: HY-145737

PROTAC SOS1 degrader-1 is a potent **PROTAC SOS1** agonist with an DC_{50} of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC SOS1 degrader-2

Cat. No.: HY-144657

PROTAC SOS1 degrader-2 is a potent **PROTAC SOS1** degrader. PROTAC SOS1 degrader-2 decreases the expression of pERK and RAS-GTP level in a dose-dependent manner. PROTAC SOS1 degrader-2 significantly inhibits the tumor growth in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rac1 Inhibitor W56

Cat. No.: HY-P1382

Rac1 Inhibitor W56 is a peptide containing residues 45-60 of Rac1. Rac1 Inhibitor W56 inhibits Rac1 interaction with guanine nucleotide exchange factors TrioN, GEF-H1, and Tiam.

MVDGKPVNLGLWDTAG

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rac1 Inhibitor W56 TFA

Cat. No.: HY-P1382A

Rac1 Inhibitor W56 TFA is a peptide containing residues 45-60 of Rac1. Rac1 Inhibitor W56 TFA inhibits Rac1 interaction with guanine nucleotide exchange factors TrioN, GEF-H1, and Tiam.

MVDGKPVNLGLWDTAG

Purity: 98.53%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RAS GTPase inhibitor 1

Cat. No.: HY-129189

RAS GTPase inhibitor 1 (example 51) is a **RAS GTPase** inhibitor with anti-tumor activity, extracted from patent WO2018212774A1. RAS GTPase inhibitor 1 (example 51) exhibits an EC_{50} less than 1 μM for at least one nucleotide exchange and an IC_{50} less than 1 μM in H727 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RAS inhibitor Abd-7

Cat. No.: HY-122862

RAS inhibitor Abd-7, a potent RAS-binding compound (K_d=51 nM), is a **RAS-effector protein-protein interaction (PPI)** inhibitor. RAS inhibitor Abd-7 interacts with RAS inside the cells, prevents RAS-effector interactions and inhibits endogenous RAS-dependent signaling.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RAS/RAS-RAF-IN-1

Cat. No.: HY-138294

RAS/RAS-RAF-IN-1 is a potent **RAS** and **RAS-RAF** inhibitor. RAS/RAS-RAF-IN-1 has a K_D of 5.0 μM-15 μM for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

Rasarfin

Cat. No.: HY-139950

Rasarfin is a dual **Ras** and **ARF6** inhibitor.
.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

RBC10

Cat. No.: HY-123464

RBC10 is an anti-cancer agent. RBC10 inhibits the binding of Ral to its effector RALBP1. RBC10 also inhibits Ral-mediated cell spreading of murine embryonic fibroblasts and anchorage-independent growth of human cancer cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RBC8

Cat. No.: HY-12873

RBC8 is a novel small molecule inhibitor of Ral GTPase; has IC50 of 3.5 μM in H2122 cell and 3.4 μM in H358 cell. IC50 value: Target: Ral GTPase inhibitor RBC8 or BQU57 treatment showed no further inhibition of colony formation after Ral knockdown.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rhosin

Cat. No.: HY-12646A

Rhosin is a potent, specific RhoA subfamily **Rho GTPases** inhibitor, which specifically binds to RhoA to inhibit RhoA-GEF interaction with a K_d of ~ 0.4 uM, and does not interact with Cdc42 or Rac1, nor the GEF, LARG. Rhosin induces cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rhosin hydrochloride

Cat. No.: HY-12646

Rhosin hydrochloride is a potent, specific RhoA subfamily **Rho GTPases** inhibitor. Rhosin hydrochloride specifically binds to RhoA to inhibit RhoA-GEF interaction with a K_d of ~ 0.4 uM, and does not interact with Cdc42 or Rac1, nor the GEF, LARG.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

RM-018

Cat. No.: HY-141477

RM-018 is a potent, functionally distinct tricomplex **KRAS**^{G12C} active-state inhibitor. RM-018 retains the ability to bind and inhibit KRAS$^{G12C/Y96D}$ and could overcome resistance. RM-018 binds specifically to the GTP-bound, active ["RAS(ON)"] state of KRAS^{G12C}.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RMC-0331

(RM-023)

Cat. No.: HY-134885

RMC-0331 (RM-023) is a potent, selective and orally bioavailable **SOS1** inhibitor. RMC-0331 is an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RTIL 13

Cat. No.: HY-115739

RTIL 13 is a potent inhibitor of **dynamin GTPase**, with an IC_{50} of 2.3 μM for **dynamin I GTPase**. RTIL 13 also targets **pleckstrin homology lipid binding domain**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SAH-SOS1A

Cat. No.: HY-P2265

SAH-SOS1A is a peptide-based **SOS1/KRAS** protein interaction inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SAH-SOS1A TFA

Cat. No.: HY-P2265A

SAH-SOS1A TFA is a peptide-based **SOS1/KRAS** protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC_{50}=106-175 nM).

Purity: 99.37%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Salirasib (S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS)

Cat. No.: HY-14754

Salirasib is a **Ras** inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.



Purity: 99.01%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

SCH 51344

Cat. No.: HY-12656

SCH 51344 inhibits Ras induced malignant transformation and prevents anchorage-independent growth of oncogene transformed fibroblasts.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SOS1 activator 1

Cat. No.: HY-111671

SOS1 activator 1 (Compound 64) is a potent activator of **SOS1**-mediated nucleotide exchange with a K_d of 44 nM. SOS1 is a guanine nucleotide exchange factor that catalyzes the exchange of GDP for GTP on RAS.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SOS1-IN-10

Cat. No.: HY-144213

SOS1-IN-10 is a potent **SOS1** inhibitor with an IC_{50} of 13 nM for KRAS G12C-SOS1 (WO2022017519A1, compound 8).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SOS1-IN-11

Cat. No.: HY-144962

SOS1-IN-11 is a potent **SOS1** inhibitor with an IC_{50} value of 30 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SOS1-IN-12

Cat. No.: HY-144965

SOS1-IN-12 is a potent **son of sevenless homolog 1 (SOS1)** inhibitor with a K_i of 0.11 nM for SOS1 and an IC_{50} of 47 nM for pERK. SOS1-IN-13 can be used for researching anticancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SOS1-IN-13

Cat. No.: HY-144967

SOS1-IN-13 is a potent **son of sevenless homolog 1 (SOS1)** inhibitor with IC_{50}s of 6.5 nM and 327 nM for SOS1 and pERK, respectively. SOS1-IN-13 can be used for researching anticancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SOS1-IN-3

Cat. No.: HY-145046

SOS1-IN-3 is a potent **SOS1 (son of sevenless homolog 1)** inhibitor with an IC_{50} of 5 nM. SOS1-IN-3 has anticancer effects (WO2019122129A1; compound I-1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SOS1-IN-4

Cat. No.: HY-145047

SOS1-IN-4 is a potent **SOS1** inhibitor with an IC_{50} of 56 nM for KRAS-C12C/SOS1 interaction (WO2021228028 A1, example 65).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SOS1-IN-5

Cat. No.: HY-145048

SOS1-IN-5 is a potent inhibitor of **SOS1**. SOS1-IN-5 is a pyrimidobicyclic derivative. SOS1-IN-5 blocks the activation of KRAS by interfering with RAS-SOS1 interaction, and achieves the purpose of broad-spectrum inhibition of KRAS activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SOS1-IN-6

Cat. No.: HY-144210

SOS1-IN-6 (compound 33-P1) is a potent **SOS1** inhibitor with IC_{50}s of 14.9 and 73.3 nM for SOS1-G12D and SOS1-G12V, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SOS1-IN-7

Cat. No.: HY-144211

SOS1-IN-7 (compound 18-p1) is a potent **SOS1** inhibitor with IC_{50}s of 20 and 67 nM for SOS1-G12D and SOS1-G12V, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SOS1-IN-8

Cat. No.: HY-144212

SOS1-IN-8 is a potent **SOS1** inhibitor with IC_{50}s of 11.6 and 40.7 nM for SOS1-G12D and SOS1-G12V, respectively (WO2022017339A1, compound 2).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SOS1-IN-9

Cat. No.: HY-144207

SOS1-IN-9 is a potent **SOS1** inhibitor with an IC_{50} of 116.5 nM for SOS1-KRAS G12C (WO2022028506A1, compound 302).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Sotorasib

(AMG-510)

Cat. No.: HY-114277

Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective **KRAS G12C** covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state.



Purity: 99.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sotorasib racemate

(AMG-510 racemate)

Cat. No.: HY-114277A

Sotorasib (AMG-510) racemate is the racemate of Sotorasib (AMG-510). AMG-510 is a potent, orally bioavailable, and selective **KRAS G12C** covalent inhibitor with anti-tumor activity.



Purity: 98.99%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg, 100 mg

StRIP16

Cat. No.: HY-136197

StRIP16, bioavailable StRIP3 analogue, is a double-stapled peptide which can bind to **Rab8a GTPase**, with a K_d of 12.7 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg

Tyrphostin 8

Cat. No.: HY-W174279

Tyrphostin 8 is a **tyrosine kinase**, with an IC_{50} of 560 μM for **EGFR kinase**. Tyrphostin 8 is also a **GTPase** inhibitor. Tyrphostin 8 can inhibit the protein **serine/threonine phosphatase calcineurin** (IC_{50}=21 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

XRP44X

Cat. No.: HY-107753

XRP44X inhibits **Ras**-induced transcription activation with the IC_{50} of 10 nM. XRP44X inhibits activation of the Ras-Erk-1/2 pathway by FGF-2. XRP44X is an inhibitor of Ras/Erk activation of **Elk3** that also affects **microtubules**.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg

Y16

Cat. No.: HY-12649

Y16 is a specific inhibitor of **Leukemia-associated Rho guanine nucleotide exchange factor (LARG)** with a K_d value of 76 nM. Y16 is active in blocking the interaction of **LARG** and related G-protein-coupled Rho GEFs with RhoA.



Purity: 99.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Z62954982

(ZINC08010136)

Cat. No.: HY-115376

Z62954982 (ZINC08010136) is a potent, selective and cell-permeable **Rac1** (IC_{50}=12 μM) inhibitor that is 4 times more effective than NSC23766 (HY-15723A) (IC_{50}=50 μM).



Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 5 mg (99.87 mM * 120.5 μL in DMSO)

ZCL278

Cat. No.: HY-13963

ZCL278 is a selective **Cdc42** modulator that directly binds to Cdc42 and inhibits its functions with K_d of 11.4 μM for Cdc42-ZCL278 affinity in surface plasmon resonance (SPR) experiment.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

ZINC09659342

Cat. No.: HY-145915

ZINC09659342 (compound 13) is an inhibitor of **Lbc-RhoA** interaction with an IC_{50} of 3.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZINC69391

Cat. No.: HY-102078

ZINC69391, a specific **Rac1** inhibitor, interferes with Rac1-GEF interaction by masking Trp56 residue on Rac1 surface. ZINC69391 interferes with the interaction of Rac1 with Dock180 and reduces Rac1-GTP levels.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZT-12-037-01

Cat. No.: HY-122866

ZT-12-037-01 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg